MedTrace Logo

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

NCT06897046 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-08-01

No results posted yet for this study

Summary

This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • II-IIIB

Interventions

DRUG

QL1706

PD-1/CTLA-4

DRUG

QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed

PD-1/CTLA4 combined chemotherapy drugs

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Shugeng Gao, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Jie Wang, MD · Shanxi Province Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2027-02-25
Completion
2027-05-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06897046 on ClinicalTrials.gov